Steven Holm

Steven focuses his practice on advising public and private companies and investors across South and Southeast Asia on strategic transactions and corporate governance.

Steven is counsel to companies across an array of industries, ranging from startups to well established companies. He is passionate about the “bits and atoms” life sciences, agtech, deeptech and cleantech ecosystem in Southeast Asia and diversifying the new economy ecosystem.

Steven has significant experience in private financings, initial public offerings (IPOs), deSPAC (special purpose acquisition company) transactions, crossover rounds, follow-on offerings, debt financing rights issues, and ongoing securities law compliance with experience in introducing regional companies to international markets. He also advises venture capital and private equity funds and investment banking firms in connection with financings.

Before joining Cooley, Steven worked in the Singapore and London offices of Milbank and Shearman & Sterling, respectively.

Steven’s representative matters include*:

Life sciences and deeptech

• Hummingbird Bioscience on its spinout and out-license of Callio Therapeutics and investment in Callio’s $187 million Series A financing in the first Singapore-linked new company (NewCo) transaction
• Enlitic on its Australian IPO and subsequent follow-on capital raise, bolt-on acquisition and secured debt financing
• Structure Therapeutics on the establishment and takedowns from its at-the-market program
• Opthea on several follow-on capital raisings and strategic transaction considerations
• Inmagene Biopharmaceuticals in its Nasdaq reverse merger with Ikena Oncology and private investment in public equity (PIPE) financing
• ASLAN Pharmaceuticals in its follow-on capital raisings, public company matters and IP-backed debt facility
• Hummingbird Bioscience in its private fundraisings and strategic transactions
• Summit Healthcare (SPAC) in its US$849 million merger with YS Biopharma and deSPAC listing on Nasdaq
• Welsbach (SPAC) in its proposed merger listing with WaveTech, a battery technology company, and deSPAC listing on Nasdaq
• The lead investor in 1NHealth’s Series A private financing
• World View in its proposed merger and deSPAC listing on the New York Stock Exchange 
• A Singapore-based medical devices company in its proposed US and Singapore IPOs 
• An Indonesia-based agtech platform in its private financings and shareholder engagement strategy
• Several Asia-Pacific-headquartered and US-listed biotech and device companies in their public company matters
• Numerous private techbio, agbio and cleantech companies in their founder relationship structuring, investor engagements, equity and convertible financings, and pilot arrangements with multinationals 

Technology

• Bitdeer Technologies Group on its $400 million principal amount of 4.00% convertible senior notes due 2031 and $147.8 million concurrent registered direct offering and derivatives transactions
• The leading regulated USD stablecoin issuer in its bolt-on M&A matters and Asia-Pacific expansion
• WeRide in its HK$2.39 billion homecoming IPO in Hong Kong and US-registered follow-on offering, following its IPO on Nasdaq
• AvePoint in its SG$260 million US Securities and Exchange Commission-registered follow-on offering with concurrent listing on the Singapore Exchange
• Several digital asset treasury (DAT) companies on their conversions from operating companies and subsequent fundraisings, as well as DAT investors
• The placement agents in the public M&A transaction involving two Association of Southeast Asian Nations (ASEAN) superapps
• The underwriters in the Indian IPO of a drone manufacturer
• Life360 in its US$179 million Nasdaq IPO and uplisting from the Australian Securities Exchange
• Bitdeer Technologies Group in its US$1.18 billion merger with Blue Safari (SPAC) and deSPAC listing on Nasdaq
• A technology-led ASEAN quick commerce chain in its Latin America expansion
• Bukalapak in its US$1.5 billion 144A Indonesian IPO*
• Triterras in one of the first Asian deSPAC transactions*
• MoneyHero in its ongoing public company matters
• Aetherium (SPAC) in its proposed US$1.15 billion merger with an arm of AirAsia and deSPAC listing
• FinAccel on its $270 million Series D private financing and proposed deSPAC transaction
• Fluid in its Series A private financing
• Tiga Acquisition Corp. in its SPAC IPO and eventual US$2.1 billion deSPAC transaction with Grindr*
• 20Cube Logistics in its proposed deSPAC transaction
• Early-stage agentic artificial intelligence (AI) companies on their venture financings and incentive structures
• A leading Singapore-based ecommerce service provider in its attempted IPO transaction
• Several fintech lenders in their private debt financing matters 
• An Indonesia-based logistics tech platform in its private financings and shareholder engagement strategy
• Several US-based software as a service multinationals on the impact of Singapore’s LNLCo regulation on their Asia-Pacific holding companies and global environmental, social and governance (ESG) reporting strategy
• Several ASEAN e-wallet providers in their private financings, shareholder engagement and exit considerations
• Numerous venture capital funds in their portfolios’ post-listing shareholder reporting and liquidity matters

Other industry verticals*

• An ASEAN stock exchange on its regulatory alignment to international IPO best practices
• The underwriters in the Indian IPO of Duroflex
• The underwriters in the Indian IPO of a leading fast-casual restaurant chain
• The underwriters in the Indian IPO of an innovative disposable consumer hygiene products manufacturer
• Bank Rakyat Indonesia in its 144A Indonesian rights issue to fund a material acquisition
• The underwriters in the Philippines IPO of DDMP REIT, the second real estate investment trust (REIT) IPO in the Philippines using an innovative structure
• ASEAN regional roll-up transactions for a technology-enabled consumer discretionary chain
• Summarecon Agung in its Reg S-only exclusionary rights issue and Reg S secondary placement
• Tele2 in its US IPO on Form F-4, following its acquisition of Com Hem
• GE Oil & Gas in its spinout of GE and merger with Baker Hughes on Form S-4
• The initial purchasers in Waberer’s 144A Hungarian IPO, the largest IPO in Hungary since 1998 and first Central and Eastern Europe sponsor IPO exit
• Lecta in its proposed 144A Luxembourg IPO
• The placement agents in several Indian accelerated offers for sale (block trades)
• The underwriters in NatWest Group’s (fka The Royal Bank of Scotland Group) F-3 shelf takedowns and F-3 renewal
• The underwriters in ArcelorMittal’s F-3 shelf takedown
• The initial purchasers in several PETRONAS 144A global medium-term note program updates and takedowns
• Indofood CBP in its inaugural Reg S issuance, one of the first investment-grade debt issuances by a non-state-linked Indonesian company
• Ongoing Securities and Exchange Commission compliance and continuous disclosure for multiple foreign private issuers and certain domestic registrants

* Includes experience from prior firms